You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中金:內地將公佈新一輪藥品帶量採購價格結果 關注競爭格局
格隆匯 09-23 10:49

中金髮表報告表示,內地第一批「4+7」(4個直轄市+7個省會城市)集採的25個藥物品種向全國推廣的價格即將在下週確定,與4+7集採方案最大的不同在於此次方案允許至多3家企業同時中選,但申報價格不得超過「4+7」集採中選藥品按現行藥品差比價規則折算後的價格。因此此次集採價格的確定與競爭格局和企業競爭策略密切相關。

該行指,從競爭格局方面,該25個品種中,按照每個品種的主品規統計(企業在申報品種時必須包含採購品種目錄指定的主品規),目前已有>3家企業具備申報資格的品種有11個;除去原研藥企,已有>3 家企業具備申報資格的品種有7個;其中氨氯地平、恩替卡韋、替諾福韋、蒙脱石散分別有12、10、11、11家企業具備申報資格;由於最終只能有≦3家企業中選,這11品種在報價過程中還將面臨較為激烈的競爭。剩餘14個品種中,目前具備申報資格的企業數量≦3家,其競爭會相對緩和。

申報價格方面,中金稱此次集採的申報價不應高於「4+7」集採中選藥品按差比價規則折算後的價格,且原則上不應高於本企業同品種今年7月31日聯盟地區省級集中採購最低價。中選企業數量,按藥品差比價規則對不同企業主品規的申報價格進行比價,報價最低的3家企業獲得擬中選資格(申報企業不足3家的以實際為準)。

中金表示,中資醫藥H股看好中國生物製藥(001177.HK)、石藥集團(01093.HK) 、威高股份(01066.HK)、國藥控股(01099.HK)、石四藥(02005.HK)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account